

Slide
1

Time to Event Analysis

Nick Holford
Dept Pharmacology & Clinical Pharmacology
University of Auckland, New Zealand

©NHG Holford, 2009, all rights reserved.

Slide
2

Outline

- The Hazard: Biological basis for survival
- The Pharmacokinetics of Survival
- Joint Models of PKPD and Time to Event
 - » Continuous
 - » Right censored
 - » Interval censored
- An Example (fracture risk reduction)


©NHG Holford, 2009, all rights reserved.

Slide
3

Why do women live longer
than men?

©NHG Holford, 2009, all rights reserved.

Slide 4



<http://www.allowe.com/Humor/whymendieyounger.htm>

Slide 5

Survival in a Bathtub




Figure 2.6 Hazard functions for all cause mortality for the US population in 1989. White males (—); white females (.....); black males (- - - - -); black females (— — — —).

"... a bathtub-shaped hazard is appropriate in populations followed from birth."
 Klein, J.P., and Moeschberger, M.L. 2003. *Survival analysis: techniques for censored and truncated data*. New York: Springer-Verlag.
http://en.wikipedia.org/wiki/Bathtub_curve "The bathtub curve"

©2003 Holt, Rinehart & Winston, all rights reserved.

The hazard describes the death rate at each instant of time. The shape of the hazard function over the human life span has the shape of a bathtub.

US mortality data shows the hazard at birth falls quickly and eventually returns to around the same level by the age of 60. The hazard is approximately constant through childhood and early adolescence. The onset of puberty and subsequent life style changes (cars, drugs,...) adopted by men increases the hazard to a new plateau which lasts for 10 to 20 years.

It would require a time varying model to describe how development (children) and ageing (adults) are associated with changes in death rate.

Slide 6

Survival and PK

	Drug	Events
Rate of loss N=people alive A=molecules remaining	$\frac{dA}{dt} = -k_{el} \cdot A$	$\frac{dN}{dt} = -\lambda \cdot N$
Hazard	k_{el}	λ
Integral	AUC	Cumulative Hazard
Non-parametric	Non-compartmental	Kaplan-Meier
Time Course	$C(t) = \exp(-k_{el} \cdot t)$	$S(t) = \exp(-\lambda \cdot t)$

©2003 Holt, Rinehart & Winston, all rights reserved.


The event rate is frequently scaled to a standard number of persons e.g. death rates per 100,000 people.

Hazard models are more typically scaled to a single person.

Pharmacokinetic models are scaled to the dose. In this example a unit dose is assumed for the time course of concentration.

Slide
7

The Kaplan-Meier Plot and Survivor Function



Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-89.

©NHG Hullford, 2009, all rights reserved.

Slide
8

Hazard and Survival

$$hazard = h(t)$$

$$CumulativeHazard(t) = \int_0^t h(t)$$

$$Survivor(t) = \Pr(T > t) = e^{-CumulativeHazard(t)}$$

$$pdf(t) = Survivor(t) \cdot h(t)$$

©NHG Hullford, 2009, all rights reserved.

The probability of a having an event at a particular time can be predicted by describing the hazard for the event. Hazard is the instantaneous rate of the event. As time passes the cumulative hazard predicts the risk of having the event over the interval 0-t.

The hazard model can be of any form but the hazard cannot be negative.

The risk is the cumulative hazard. It is obtained by integrating hazard with respect to time.


The probability of survival (not having the event) can be predicted from the cumulative hazard. This is called the survivor function.

The probability of having an event at a particular time is predicted by the probability density function (pdf(t)). The pdf can be calculated from the survivor function and hazard at that time.

The cumulative density is the integral of the pdf.

Slide
9

Survivor Function



©NHG Hullford, 2009, all rights reserved.

beta0=1
betaWB=1
betaTRT=-logn(2)

```
hazpla=if (time>0) then
beta0*exp(betaWB*logn(time)) else 0
haztrt=if (time>0) then
beta0*exp(betaWB*logn(time)+betaTRT)
else 0
```


```
init(cumpla)=0
d/dt(cumpla)=hazpla
survpla=exp(-cumpla)
```

```
init(cumtrt)=0
d/dt(cumtrt)=haztrt
survtrt=exp(-cumtrt)
```

```
pdfpla=survpla*hazpla
pdftrt=survtrt*haztrt
```

Slide
10


Cumulative Hazard and Relative Risk



©NHG Holland, 2009, all rights reserved.

Slide
11

Probability Density Function



©NHG Holland, 2009, all rights reserved.

Slide
12

Pharmacokinetic Survival Non-Linear

$$\text{hazard}(t) = \text{Rateconstant}(t) = \frac{V_{\max}/V}{K_m + C(t)}$$

$$\text{Risk}(t) = \text{CumConstant}(t) = \int \text{Rateconstant}(t)$$

$$\text{Survival}(t) = C(t) = e^{-\text{CumConstant}(t)}$$

©NHG Holland, 2009, all rights reserved.

If the hazard varies with time (or a function of time, such as concentration) then exactly the same relationships between hazard, risk and survival exist as for the constant hazard case. It is possible to make non-linear pharmacokinetic model predictions of the amount eliminated and the time course of concentration using survival analysis functions.

Slide
13

Non-linear PK and Survival

```

dose=100
v=1
vmax=100
km=50

rateconstant=(vmax/v)/(km+conc)
init(conc)=dose/v
d/dt(conc)=-rateconstant*conc

init(cumconstant)=0
d/dt(cumconstant)=rateconstant
survival=dose*exp(-cumconstant)


```

Time	Conc	Survival
0	100	100
1	42.6303	42.6303
2	10.8858	10.8858
3	1.76793	1.76793
4	0.246655	0.246655
5	0.033524	0.033524
6	0.00454	0.00454
7	6.14E-04	6.14E-04
8	8.32E-05	8.32E-05
9	1.13E-05	1.13E-05
10	1.52E-06	1.52E-06

©NHG Holland, 2009, all rights reserved.

Slide
14

Distribution of Survival Times Michaelis-Menten Elimination



$$\text{Survival}(t) = e^{-\int_0^t \text{hazard}(t) dt}$$

$$\text{PDF}(t) = \text{Survival}(t) \cdot \text{hazard}(t)$$

©NHG Holland, 2009, all rights reserved.

A useful view of survival is to look at the probability density function for the survival times.

Slide
15

Baseline Hazard Functions

$$h(t) = \lambda \quad \text{Exponential}$$

$$h(t) = \lambda \cdot \gamma \cdot t^{\gamma-1} \quad \text{Weibull}$$

$$h(t) = \lambda \cdot \gamma \cdot e^{(\gamma-1) \cdot \ln(t)}$$

$$h(t) = \beta_0 \cdot e^{\beta_1 \ln(t)}$$

$$h(t) = \lambda \cdot e^{\beta_1 \cdot t} \quad \text{Gompertz}$$

Parametric: Can be used for simulation and time varying hazards

$$h(t) = \text{Similar for everyone but undefined} \quad \text{Cox Proportional}$$

Non-Parametric: No good for simulation. Tricky with time varying hazards.

©NHG Holland, 2009, all rights reserved.

The hazard function is associated with a distribution of event times. Some common distributions have names e.g. Gompertz (one of the first mathematicians to explore survival analysis). Standard baseline hazard functions used by statisticians are chosen for their mathematical simplicity rather than any biological reason. The biology of event time distributions is largely based on descriptive and empirical approaches. However, the hazard is the way to introduce biological mechanism and understanding the variability of time to event distributions.

Slide 16

Explanatory Variable Functions

$$h(t) = \beta_0 \cdot e^{\beta_1 \cdot x_1 + \beta_2 \cdot x_2 \dots + \beta_n \cdot x_n}$$

Includes exponential, Weibull, Gompertz as special cases

$$h(t) = \beta_0 \cdot e^{f(B, X)}$$

Linear and non-linear functions of explanatory variables

©NHG Halford, 2009, all rights reserved.

The explanatory variable function is quite empirical. This form is used because there are some simple solutions for integrating the hazard and the exponential form ensures that the hazard is always non-negative.

Slide 17

Exponential Coefficients and the Hazard Ratio

$$h(t) = \beta_0 \cdot e^{\beta_1 \cdot x_1 + \beta_{SEX} \cdot SEX \dots + \beta_n \cdot x_n}$$

If the explanatory variable is 0 for females and 1 for males and the value of β_{SEX} is 0.693 then the hazard ratio for men is 2 (compared to women).

©NHG Halford, 2009, all rights reserved.

The coefficients of the exponential function are convenient for describing how the hazard varies with the explanatory variable. Exponentiation of the coefficient gives the hazard ratio for the effect of the explanatory variable.

Slide 18

How can the effect of treatment $Rx(t)$ be described?




Figure 2.6 Hazard functions for all cause mortality for the US population in 1989. White males (—); white females (.....); black males (- - - -); black females (- · - · -).


$$h(t) = f(\text{sex, race, age}(t), Rx(t), \dots)$$

©NHG Halford, 2009, all rights reserved.

Standard survival analysis can include varying age implicitly. Adding time-varying covariates for survival analysis is harder to do because of the need to integrate the hazard. Drug treatments will often change with time and if expressed in terms of drug concentration the hazard could change in proportion to concentration after every dose.

Slide 19

Hazard models link disease progress and clinical outcome probability



©NHG Halford, 2009. All rights reserved.

Slide 20

Joint Models

- Basic concept
 - Compute LIKELIHOOD for ANY kind of response
- Predict likelihood of time of event instead of the time of event
- All types of response can be combined

©NHG Halford, 2009. All rights reserved.

Any kind of response, continuous or non-continuous, can be combined in a NONMEM model by using the joint likelihood computed for each observation. It is up to the user to compute the likelihood (or -2LL) for any non-continuous responses. In NONMEM VI the F_FLAG variable is used to distinguish the type or prediction being made. In NONMEM V user written CCONTR is used to tell NONMEM how to compute the likelihood (or -2LL) for continuous responses.

Slide 21

Applications

- Continuous Response
 - » Standard PKPD
- Non-continuous Response
 - » Binary Response
 - Awake or Asleep
 - » Ordered Categorical Response
 - Neutropenic adverse event type
 - » Count Response
 - Frequency of epileptic seizures
 - » Time to Event
 - Bone fracture
 - » Dropout
 - Missing data
- Joint Response
 - » Continuous plus non-continuous

©NHG Halford, 2009. All rights reserved.

NONMEM (and many other parameter estimation procedures) uses the likelihood to guide the parameter search. The likelihood is the fundamental way to describe the probability of any observation given a model for predicting the observation. NONMEM shields us from the details for common PKPD models that use continuous response scales for the observation (e.g. drug concentration, effect on blood pressure).

A variety of non-continuous responses are widely used to describe drug effects – especially clinical outcomes. By computing the likelihood directly for each of these kinds of response we can ask NONMEM to estimate parameters for any mixture of response types.

<p>Slide 22</p>	<h2 style="text-align: center; color: red;">NONMEM</h2> <ul style="list-style-type: none"> ● NONMEM Maximises the Likelihood ● \$ESTIMATION METHOD=CONDITIONAL LAPLACIAN LIKE or -2LL <p style="font-size: small; text-align: left;">©NHG Holford, 2009, all rights reserved.</p>	<p>NONMEM maximises the likelihood when estimating parameters.</p> <p>There is a pair of default subroutines (CCONTR and CONTR) that are used to compute the Conditional CONTRibution to the likelihood.</p> <p>The NM-TRAN \$ESTIMATION record can have an option that allows the user to directly return the likelihood or -2LL instead of letting NONMEM compute it with its CCONTR and CONTR subroutines. This option always requires the CONDITIONAL method (FOCE) and is thought to work better if the LAPLACIAN option is used. NONMEM VI allows the user to perform joint modelling of different types of data by using the F_FLAG variable to indicate what is returned by the prediction for Y.</p>
<p>Slide 23</p>	<h2 style="text-align: center; color: red;">Likelihood for Continuous Variable</h2> $Like_{ij} = \exp \left[-0.5 \cdot \left(\left(\frac{Y_{OBS,ij} - Y_{PRED,ij}}{SD_{ij}} \right)^2 + \ln \left(D^2_{ij} \cdot 2\pi \right) \right) \right]$ <p style="font-size: small; text-align: left;">©NHG Holford, 2009, all rights reserved.</p>	<p>For a continuous response type (the default for NONMEM) the likelihood is computed using the extended least squares objective function (ELS). Each observation (Yobs) and each prediction (Ypred), along with the predicted variance of the difference between Yobs and Ypred (Var) are used to compute a contribution to the ELS objective function. This contribution is summed over all subjects and all observations to compute -2 times the log of the likelihood. Actually its not quite -2LL but proportional to it. It is missing a constant (NOBS*Ln(2*Pi)) but this is not needed in order to minimize -2LL and obtain maximum likelihood estimates.</p> <p>The likelihood of non-continuous types of event will depend on the type of event. The likelihood of an event at time t is given by the probability density function at that time.</p>
<p>Slide 24</p>	<h2 style="text-align: center; color: red;">Likelihoods for Survival</h2> <p>For an uncensored datum, with T_i equal to the age at death, we have</p> $\Pr(T = T_i \theta) = f(T_i \theta) = S(T_i \theta) * h(T_i)$ <p>For a left censored datum, such that the age at death is known to be less than T_i, we have</p> $\Pr(T < T_i \theta) = F(T_i \theta) = 1 - S(T_i \theta)$ <p>For a right censored datum, such that the age at death is known to be greater than T_i, we have</p> $\Pr(T > T_i \theta) = 1 - F(T_i \theta) = S(T_i \theta)$ <p>For an interval censored datum, such that the age at death is known to be greater than $T_{i,r}$ and less than $T_{i,l}$, we have</p> $\Pr(T_{i,l} < T < T_{i,r} \theta) = S(T_{i,l} \theta) - S(T_{i,r} \theta)$ <p style="text-align: center;">http://en.wikipedia.org/wiki/Survival_analysis</p> <p style="font-size: small; text-align: left;">©NHG Holford, 2009, all rights reserved.</p>	

Slide 25

Time Varying Hazard (CP) With Right Censoring using NONMEM

```

$ESTIM MAXEVAL=9990 METHOD=COND
LAPLACE LIKE
$THETA
10 FIX ; POP_CL
100 FIX ; POP_V
0.1 ; POP_BETA
(0,0.01) ; BASE
;Random effect for baseline hazard
$OMEGA 0.01 ; PPV_HAZ
$SUBR ADVAN=6 TOL=3
$MODEL
COMP=(CENTRAL)
COMP=(CUMHAZ)
$PK
CL=THETA(1)
V=THETA(2)
BETA=THETA(3)
BASHAZ=THETA(4)*EXP(ETA(1))

$DES
DCP=A(1)/V
DADT(1)=-CL*DCP
DADT(2)=BASHAZ*EXP(BETA*DCP)
$ERROR
CP=A(1)/V
RISK=A(2) ; cumulative hazard
SURV=EXP(-RISK)
IF (DV.EQ.0) THEN
Y=SURV ; right censored event
ELSE
HAZNOW=BASHAZ*EXP(BETA*CP)
Y=SURV*HAZNOW ; Like of having an
; event at time=TIME
ENDIF

```

©NMG-Holford, 2009, all rights reserved.

Estimation of the parameters of any hazard model can be done using this kind of code. It uses ADVAN6 to integrate the hazard and obtain the cumulative hazard. The cumulative hazard is used in \$ERROR to calculate the probability of survival (SURV) i.e. the likelihood of not having the event at a particular time (DV=0). If the event occurs (DV=1) at the time of the record then the likelihood is determined by the probability density function at that time i.e. $S(t) \cdot h(t)$.

Slide 26

Right Censored Data Single Event

#ID	TIME	DV	AMT	Comment
1	0	0	100	Dose
1	50	1	0	Event
2	0	0	100	Dose
2	75	1	0	Event
3	0	0	100	Dose
3	100	0	0	Censored Event
4	0	0	100	Dose
4	25	1	0	Event
5	0	0	100	Dose
5	100	0	0	Censored Event

©NMG-Holford, 2009, all rights reserved.

Single event observations (e.g. death) have just one observation event.

Slide 27

Interval Censored Time to Event

IF (DV.EQ.0) ; right censored event at t

$$Like_{NoEvent} = S(t) = e^{-\int_0^t h(t)} dt$$

ELSE ; event between $t_{lastobs}$ and t_{end}

$$Like_{Event} = S(t_{lastobs}) - S(t_{end}) = e^{-\int_0^{t_{lastobs}} h(t)} dt - e^{-\int_0^{t_{end}} h(t)} dt$$

©NMG-Holford, 2009, all rights reserved.

Using NONMEM nomenclature, DV is a the observed event state. If it is 0 it means the subject has not had the event. If it is 1 then the subject had an event at some time between the last observation the end time when it is known they have had an event since the last observation time. At the time a subject is known to have dropped out (DV=1) the likelihood of dropping out in the interval between the last observed time and the end time is given by the difference in the survivor function at the last observed time and the survivor function at the end time. These two survivor functions can be computed from cumulative hazards from 0 to the last observed time and from 0 to the end time.

Slide 28

Disease Progress and Time Varying Hazard with Interval Censoring (NM7 or NMVI)

```

$INFOR ID TRT TIME DV DVID
$ESTIM MAX=9990 SIG=6 NOABORT
METHOD=CONDITIONAL LAPLACE
$SUBR ADVAN=6 TOL=6
$MODEL
COMP=(CUMHAZ)

$PK
IF (NEHIND.LE.1) SRVZ=1 ; Survival(0) is 1
BSHZ=THETA(1) ; Baseline hazard
BETADP=THETA(2) ; Disease progress hazard
EFFECT=TRT*THETA(3)
INTRI=(THETA(4)+EFFECT)*EXP(ETA(1))
SLOPI=THETA(5)*EXP(ETA(2))

$DES
DISFRG=INTRI + SLOPI*T
EXPHAZ=EXP(BETADP*DISFRG)
DADT(1)=BSHZ*EXPHAZ ; h(t)

$ERROR
CHZT=A(1) ; Cum hazard at this time
IF (DVID.NE.2) THEN
  F_FLAG=0 ; CONTINUOUS ELS
  Y=INTRI + SLOPI*TIME + ERR(1) ; Biomarker
ENDIF
SRVT=EXP(-CHZT) ; Survival at t
IF (DVID.EQ.2.AND.DV.EQ.0) THEN
  F_FLAG=1 ; LIKELIHOOD
  Y=SRVT ; Like no event
ENDIF
IF (DVID.EQ.2.AND.DV.EQ.1) THEN
  F_FLAG=1 ; LIKELIHOOD
  Y=SRVZ-SRVT ; Like event
ENDIF
IF (DVID.EQ.3) THEN ; Last obs before event
  SRVZ=SRVT ; remember survival
ELSE
  SRVZ=SRVZ ; keep NM-TRAN happy
ENDIF

```

©NHG Hubford, 2009, all rights reserved.

This illustrates joint modelling for disease progress and an event. The event hazard depends on disease progress. A differential equation is used to integrate the hazard. An effect of treatment (TRT) is assumed to affect the intercept of the disease progress model which in turn influences the hazard of the event.

When using NMVI it is possible to save the value of the survivor function even if the hazard involves a random variable (i.e. an ETA is used in the computation). The same method can be used with NMV if there is no random variable in the hazard. In this example DVID=3 is used to indicate the start of the interval censored event period and the survivor function (SRVT) is saved in the variable SRVZ. Note to keep NM-TRAN happy it is necessary to explicitly include the assignment of SRVZ for records with DVID not equal to 3.

The F_FLAG variable is used to tell NONMEM how to use the predicted Y value. F_FLAG of 0 is the default i.e. Y is the prediction of a continuous variable. F_FLAG of 1 means the prediction is a likelihood. F_FLAG of 2 means the prediction is -2*ln(Likelihood).

Slide 29

Interval Censored Data (NM7 or NMVI)

#ID	TRT	TIME	DV	DVID	Comment
1	1	0	-0.6	1	Biomarker Obs
1	1	25	28.1	1	Biomarker Obs
1	1	50	53.2	1	Biomarker Obs
1	1	75	81.8	1	Biomarker Obs
1	1	100	108.7	1	Biomarker Obs
1	1	100	0	2	Censored Event
2	0	0	0.1	1	Biomarker Obs
2	0	25	28.8	3	Last Non-event Obs
2	0	50	1	2	End Event Interval

ID 2: Event is between time 25 and 50.

©NHG Hubford, 2009, all rights reserved.

The NONMEM VI dataset format is shown here (can be used with NMV if the hazard does not involve a random variable) When DVID is 1 this means the DV observation is of the disease state (e.g. viral load). When DVID is 2 this means the DV observation is event status (0=censored event, 1=had event) When DVID is 3 this means this is the last observation time before the interval censored event In this example the first subject did not have an event during the study and the final record has DV=0 to indicate this. The second subject had an event between time 25 and 50. The DVID is 3 at time 25 to indicate this is the last time the subject was known not to have the event. The final record for this subject indicates that they were known to have had the event by time 50. The TRT data item is 0 for placebo and 1 for active treatment. The LOCF data item is used when testing the random missingness model.

Slide 30

Bone Fractures and Hormone Replacement Therapy


Integration of PKPD, Disease Progress and Hazard to Explain the Time Course of Benefit

©NHG Hartford, 2009. All rights reserved.

Slide 31

Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density The Women's Health Initiative Randomized Trial

Jane A. Cauley, DrPH
John Robbins, MD
Zhao Chen, PhD
Steven R. Cummings, MD
Rebecca D. Jackson, MD
Andrea Z. LaCroix, PhD, MPH
Meryl LeBoff, MD
Cora E. Lewis, MD, MSPH
Joan McGowan, PhD
Joan Neuner, MD, MPH
Mary Pettinger, MS
Marcia L. Stefanick, PhD
Jean Wactawski-Wende, PhD
Nelson B. Watts, MD
for the Women's Health Initiative Investigators




JAMA, 2003;290:1729-1738

©NHG Hartford, 2009. All rights reserved.

NOTE: Ca/vitamin D at doses administered show increases in BMD without added reduction in fracture (hip and total fracture) Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus Vitamin D Supplementation and the Risk of Fractures. N Engl J Med. 2006 February 16, 2006;354(7):669-83.

Slide 32


Bone Mineral Density – Slow Biomarker Women's Health Initiative Randomized Trial



©NHG Hartford, 2009. All rights reserved.

The Women's Health Initiative trial observed the time course of changes in bone mineral density in 1000 women who were treated with placebo or with hormone replacement therapy. Both groups were treated with vitamin D and calcium. Half of the placebo patients were given placebo vitamin D and calcium. This plot is a visual predictive check showing the median and 90% interval for the observed (black) and predicted (red) BMD changes. The increase in BMD in the placebo group (and some of the change in the HRT group) is attributable to treatment with vitamin D and calcium.

Slide 33



These figures shows some key results for the Hip and Spine models which represent the two different types of bone.


Teq for lumbar spine 0.81 y. Teq for hip 1.53 y.

For the hip bone, there was a trend for bone loss with a progression rate of less than 0.01% per year. Maximum treatment effect was estimated to be 6% of baseline. But by year 6, 94% of treatment effect was observed.

For spine, women gained bone mass during the trial. Approximately 52% of the women's progression rate was 0.1% per year and the remaining women gained bone with a rate of 0.5% per year.

Maximum treatment effect from hormones was approximately 6% of baseline. Due to the shorter equilibration T1/2, maximum treatment effect was observed by year 4.

Slide 34




Key to our modeling approach was to specify the hazard model for fractures as a function of Bone Mineral Density.

Instead of using the predicted BMD as a single time-varying covariate in the hazard, we chose to parameterize the hazard function by including each component of the disease status model as a covariate. This allowed us to assess the relative contributions of each component to the risk of fracture.

Some women had more than one fracture which allowed the between subject difference in hazard to be estimated (η). This kind of random effects model is called a 'frailty model' in the statistical survival analysis literature.


Slide 35




This is a deterministic simulation of the final fracture model using total body BMD

NOTE: Ca/vitamin D at doses administered show increases in BMD without added reduction in fracture (hip and total fracture. JAMA 2006)

Slide 36




Slide 37



The slide shows a predictive check using the Kaplan-Meier method to generate the predicted uncertainty in the survivor function (based on 500 replications of the WHI data set). The 90% predictive interval for placebo is shaded in orange and the blue represents the predictive interval for E+P. The black lines represent the observed probability of no fracture. Overall, we concluded that the model describes the observed data well.

Slide 38



Slide 39

Backup Slides

Slide 40

Joint Model NMV

```

$DATA ID TIME AMT TYPE DV
$ESTIM MAXVAL=9999 METHOD=COND LAPLACE
NOASORT
: Non-continuous response
BASE=LOG(BASEP/(1-BASEP))
LOGT=BASE + BETA*CF + PPV_EVENT
ODDS=EXP(LOGT)
P1=ODDS/(1+ODDS)
IF (DV.EQ.1) ODDEST=P1
IF (DV.EQ.0) ODDEST=1-P1
$SUBROUTINE ADVAN=2 TRAN=2
CCONTR= . \ccontr_1like.for
CONTR= . \ccontr.for
$CONTR DATA=(TYPE)
: Continuous response
$ERROR
IF (TYPE.LE.2) THEN
Y=CFEST ; continuous
ENDIF
IF (TYPE.EQ.3) THEN
Y=ODDEST ; non-continuous
ENDIF
CF=PP
CFEST=CF + ruv_sd

```

This is a simple example of a continuous response (PK model defined with ADVAN2) and a non-continuous binary response (defined by a logistic model). The TYPE data item is used to signal in \$ERROR which kind of response to return in the variable Y. The \$CONTR record tells the CCONTR subroutine what meaning it should attach the TYPE data item.

Slide 41

CCONTR

```

SUBROUTINE CCONTR (ICALL, CNT, P1, P2, IERR1, IERR2)
SAVE
C IERR and NO should match values in $ERROR
PARAMETER (LOW=30, HD=50)
COMMON /ROCM4/ Y(IN), DATA(HD,3)
DOUBLE PRECISION CNT,P1,P2,Y
DIMENSION P1(Y),P2(LOW,*)
TYPE=DATA(1,1)
C Value of TYPE is provided as a user defined data item
IF (TYPE.EQ.1) THEN
C CELS is used for continuous type data
CALL CELS(CNT,P1,P2,IERR1,IERR2)
ELSE
C CLIK is used for LITE or -LIL
C IERR1 argument is 1 for LITE and 3 for -LIL
CALL CLIK(1,CNT,P1,P2,IERR1,IERR2)
ENDIF
RETURN
END

```

The format of the user supplied CCONTR is shown here. It can be used quite generally. The main user specific feature is to use the value of TYPE (which is determined by a value in the data set) to choose which method should be used to compute the contribution to the likelihood.

Slide 42

Time Varying Hazard with Interval Censoring (NMV)

```

SIMPT ID THE TIME ONT LOCF
DV MEV DVID
SESTIN MAX=9999 SIG=6 H0R08RT
METH00=CONDITIONAL LAPLACE

SC08T8 DATA=(DVID)
S0808 AC08M=6 T08=6
C08P=0808T FOR C08P08T=0808T_Like_For

MODEL
C08M=(C08M01)
C08M=(DELTA,INITIALOFF)

IFE
B08M=(BETA(1) ; Baseline hazard
BETA=(BETA(2) ; Random missing
B08T=(BETA(3) ; Informative missing
B08T0=(BETA(4)
E08E1=(BETA(5)+EFFECT)*EXP(ETA(1))
SLOP=(BETA(6)+EXP(ETA(2))

$E08
$E08M0=(BETA(1) + SLOP)*
EXP(M08M*(BETA(1) + BETA(2)+SLOP))
D08T(1)=EXP(M08M ; Observed + Unobserved h(t)
D08T(2)=EXP(M08M ; Unobserved h(t)

$E08C
C08T=M08M*(1) ; Cum hazard overall
C08T=M08M*(2) ; Cum hazard from last obs
C08T=C08T-C08TINT ; Cum hazard upto last obs
IF (DVID.NE.1) THEN
  T=C08T + SLOP*(TIME + SEB(1)) ; Biomarker
ENDIF
SEVT=EXP(-C08T) ; Survival at t
IF (DVID.NE.2 AND.DV.NE.0) THEN
  T=SEVT ; Like an event
ENDIF
IF (DVID.NE.2 AND.DV.NE.1) THEN
  SEVT=EXP(-C08T) ; Survival at t
  T=SEVT/SEVT ; Like event
ENDIF

```

NMV requires a more complex data structure and two differential equations if there is a random effect used to compute the hazard. The data table has to turn on the second integration compartment at the start of the interval during which the event occurs. The cumulative hazard up to the start of this interval is then computed by subtracting the hazard cumulated in the interval from the cumulative hazard at the end of the interval.

Slide 43

Interval Censored Data (NMV)

#ID	TRT	TIME	CMT	LOCF	DV	MDV	DVID	EVID	Comment
1	1	0	1	0	-0.6	0	1	0	Biomarker Obs
1	1	25	1	-0.6	28.1	0	1	0	Biomarker Obs
1	1	50	1	28.1	53.2	0	1	0	Biomarker Obs
1	1	75	1	53.2	81.8	0	1	0	Biomarker Obs
1	1	100	1	81.8	108.7	0	1	0	Biomarker Obs
1	1	100	1	108.7	0	0	2	0	Censored Event
2	0	0	1	0	0.1	0	1	0	Biomarker Obs
2	0	25	1	0.1	28.8	0	1	0	Last Non-event Obs
2	0	25	2	28.8	0	1	0	2	Turn On Cum Hazard
2	0	50	1	28.8	1	0	2	0	End Event Interval

ID 2: Event is between time 25 and 50.
Cumulative Hazard compartment is turned on at 25 (CMT=2).

The NONMEM V dataset format is shown here. When DVID is 1 this means the DV observation is of the disease state (e.g. viral load). When DVID is 2 this means the DV observation is event status (0=censored event, 1=had event). The CMT data item is set to 2 at the time of the last observation prior to the event. This turns on this compartment so that it accumulates the hazard of the event. In this example the first subject did not have an event during the study and the final record has DV=0 to indicate this. The second subject had an event between time 25 and 50. A special event record (EVID=2) is used to set the CMT variable to 2 and turn on the second compartment. The final record for this subject indicates that they were known to have had the event by time 50. The TRT data item is 0 for placebo and 1 for active treatment. The LOCF data item is used when testing the random missingness model.

Slide 46

Parametric Regression In Standard Packages

- Estimation of hazard parameters is done after transformation e.g. $\ln(T)$
- Explanatory variable model is then linear regression e.g. for Weibull

$$\ln(T_i) = \frac{1}{\gamma} \ln(\lambda) - \beta_1 \cdot x_{i1} - \beta_2 \cdot x_{i2} - \dots - \beta_p \cdot x_{ip} + \varepsilon_i$$

Or more generally

$$\ln(T_i) = \mu + \alpha_1 x_{i1} + \alpha_2 x_{i2} + \dots + \alpha_p x_{ip} + \sigma \cdot \varepsilon_i$$

Note that covariates ($x_1 \dots x_p$) are usually assumed to be time invariant
Standard survival analysis is equivalent to non-compartmental PK

When covariates change with time then the hazard must be integrated in a piecewise fashion. This is exactly analogous to PK problems. If clearance changes from one time period to the next then the concentration prediction must be done piecewise (NONMEM describes this as 'advancing the solution')

Slide 47

Combined Response Models

- Continuous Response
 - » Standard PKPD
 - Bone Mineral Density
- Non-continuous Response
 - » Time to Event
 - Treatment Discontinuation
 - Bone fracture
- Combined Response
 - » Continuous plus non-continuous


NONMEM (and many other parameter estimation procedures) uses the likelihood to guide the parameter search. The likelihood is the fundamental way to describe the probability of any observation given a model for predicting the observation. NONMEM shields us from the details for common PKPD models that use continuous response scales for the observation (e.g. drug concentration, effect on blood pressure).

A variety of non-continuous responses are widely used to describe drug effects – especially clinical outcomes. By computing the likelihood directly for each of these kinds of response we can ask NONMEM to estimate parameters for any mixture of response types.

Slide 48

Randomization Test Simulated Linear Disease Progress Plus CRD

1000 subjects observed at $t = 0, 25, 50, 75$ and 100
 1000 replications; RD and ID: One extra parameter
 Bootstrap: mean and 95% confidence interval
 Slope: 1 within SD: 1 u
 Baseline: 0.01
 ID hazard: 0.0
 Average Dropout: 50% (95 percentile: 47-53%)
 Type I error rate: 5%



Model Comparison	CritOBJ	Low	High	F success
Null: CRD Alternate: RD	3.75	3.27	4.25	95%
Null: CRD Alternate: ID	3.67	3.33	4.17	95%

Hu and Sale investigated the three models for missingness using real data sets. They distinguished between the models by assuming the difference in -2 times the log likelihood was distributed according to the chi-square distribution.


This assumption was tested by simulating data under the completely random dropout model and then fitting it with the same model and with the random and informative dropout models.

The probability of being observed to have dropped out is shown using the CRD model in the graph. Overall about 50% of subjects are expected to drop-out during the time from 0 to 100.

The addition of one extra parameter with either the RD or ID models required a large change in objective function to reject the null with a 5% Type I error rate. Over 90% of runs minimized successfully with both the null model (CRD) and the alternate model (RD or ID).

LIKE vs -2LL Methods ID Bias and Imprecision

1000 subjects observed at $t = 0, 25, 50, 75$ and 100
 100 replications
 Slope 1 u/time SD 1 u
 Baseline 0.0001
 ID Hazard 0.065
 Average Dropout 53% (95 percentile 50-56%)



	LIKE				-2LL			
	Bias	Success	79%	7 h 4 min	Bias	Success	44%	7h 53 min
	Bias	ICI	ICI	RMSE	Bias	ICI	ICI	RMSE
Slope	0.01%	-0.14%	0.17%	0.7%	0.1%	-0.11%	0.3%	0.67%
PPVslope	-0.15%	-0.77%	0.46%	2.7%	-0.23	-0.77	0.32	2.6%
Baseline	2.3%	-1.3%	5.6%	15.6%	10%	11%	17%	10%
ID hazard	-0.16%	-0.8%	0.5%	2.9%	-2.2%	-2.7%	-1.7%	1.7%

©2006 Biometrics, all rights reserved.

The influence of using the two different methods (CCONTR and -2LL) for computing the contribution to the likelihood was investigated by Monte Carlo simulation. The probability of being observed to have dropped out is shown using an informative dropout model in the graph. Overall about 50% of subjects are expected to drop-out during the time from 0 to 100.

A disease progress observation was made on up to 4 occasions after entry to the study. During simulation the ID model was used to predict if drop-out occurred between the last visit and the current visit. A linear disease progress model with fixed intercept of 0 was used to describe the disease progress state. Simulated data were then fitted to the ID model using NONMEM.

The CCONTR method was faster and slightly more NONMEM runs minimized successfully. The bias and imprecision of the parameter estimates was similar for both methods. There were major biases in the estimated of the baseline and informative dropout hazard parameters.